Experienced trio to guide Immodulon's IMM-101 through late clinical development

10 May 2023

UK-based cancer immunotherapy company Immodulon has named Richard Davies as its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer.

Together, they bring decades of industry experience from drugmakers including Celgene, Amgen (Nasdaq: AMGN), Hospira, ADC Therapeutics (NYSE: ADCT) and Alvotech (Nasdaq: ALVO). Immodulon sees their expertise as important in guiding IMM-101 through late-stage clinical development and maximizing its potential for patients.

"Immodulon has generated compelling Phase II data with IMM-101, which has the potential to make a real impact on the treatment of pancreatic cancer where patients have limited new treatment options"Mr Davies, who is currently deputy chairman of the board of directors for Alvotech and was formerly chief commercial officer at Hospira, said: “I am excited to join Immodulon’s board of directors as chairman at this pivotal time for the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK